Jove
Visualize
Contact Us

Related Experiment Videos

Antiplatelet agents and stroke prevention

M L Dyken1

  • 1Stroke Journal, Indianapolis, IN 46202, USA.

Seminars in Neurology
|February 5, 1999
PubMed
Summary

Aspirin (acetylsalicylic acid) effectively prevents secondary strokes. Higher doses may offer enhanced benefits, though evidence is limited, and it serves as an alternative to warfarin for atrial fibrillation patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Notice of duplicate publication.

Stroke·1999
Same author

Secondary prevention for stroke after CAPRIE and ESPS-2. Opinion 2.

Cerebrovascular diseases (Basel, Switzerland)·1998
Same author

Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.

Circulation·1997
Same author

American Heart Association Prevention Conference. IV: Prevention and Rehabilitation of Stroke. Keynote Address: properly designed trials and identification of risk factors.

Stroke·1997
Same author

Antithrombotic therapy for cerebrovascular disorders. An update.

Chest·1995
Same author

Overview of trends in management and prognosis of stroke.

Annals of epidemiology·1993
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Neurology
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Aspirin (acetylsalicylic acid, ASA) is a cornerstone in secondary stroke prevention.
  • Optimal dosing strategies for ASA in stroke prevention remain an area of investigation.

Purpose of the Study:

  • To review the efficacy of aspirin (ASA) in secondary stroke prevention.
  • To evaluate the role of different ASA dosages and combination therapies.

Main Methods:

  • Literature review of studies on aspirin, ticlopidine, clopidogrel, dipyridamole, and warfarin in stroke prevention.
  • Analysis of evidence regarding ASA dosage and its impact on stroke risk reduction.

Main Results:

  • ASA (75-1300 mg/day) is effective for secondary stroke prevention.
  • Higher ASA doses may enhance efficacy, but robust evidence is lacking.
  • Clopidogrel and ticlopidine show comparable or superior efficacy to certain ASA doses.
  • Adding dipyridamole to ASA has shown mixed results, with no clear benefit over higher-dose ASA alone.
  • ASA is a viable alternative to warfarin for atrial fibrillation patients with contraindications.

Conclusions:

  • Aspirin remains a primary choice for secondary stroke prevention, with potential benefits from higher doses.
  • Combination therapies require further investigation, as higher-dose ASA alone may suffice.
  • ASA is recommended for specific patient groups, but not for low-risk asymptomatic elderly individuals without further study.

Related Experiment Videos